{"anticipatedPostingDate":"2026-08","denomUnitsSelected":"Participants","reportingStatus":"NOT_POSTED","timeFrame":"Time between date of randomization and the date of disease progression/relapse on the basis of investigator-assessment, death, or start of a new anti-leukemic therapy, up to 10.75 years","title":"Event-Free Survival","type":"SECONDARY"}